The inclusion of diagnostics in national health insurance schemes in Cambodia, India, Indonesia, Nepal, Pakistan, Philippines and Viet Nam

Jacob Bigio,1,2 Emma Hannay,3 Madhukar Pai,4 Bachi Alisjahbana,5 Rishav Das,1,2 Huy Ba Huynh,6 Uzma Khan,7 Lalaine Mortera,8 Thu Anh Nguyen9,10 Muhammad Aamir Safdar,11 Suvesh Shrestha,12 A Venkat Raman,13 Sharat Chandra Verma,14 Vijayashree Yellappa15 Divy Srivastava16

ABSTRACT
The Lancet Commission on Diagnostics highlighted a huge gap in access to diagnostic testing even for basic tests, particularly at the primary care level, and emphasised the need for countries to include diagnostics as part of their universal health coverage benefits packages. Despite the poor state of diagnostic-related services in low-income and middle-income countries (LMICs), little is known about the extent to which diagnostics are included in the health benefit packages. We conducted an analysis of seven Asian LMICs—Cambodia, India, Indonesia, Nepal, Pakistan, Philippines, Viet Nam—to understand this issue.

We conducted a targeted review of relevant literature and applied a health financing framework to analyse the benefit packages available in each government-sponsored scheme. We found considerable heterogeneity in country approaches to diagnostics. Of the seven countries, only India has developed a national essential diagnostics list. No country presented a clear policy rationale on the inclusion of diagnostics in their scheme and the level of detail on the specific diagnostics which are covered under the schemes was also generally lacking. Government-sponsored insurance expansion in the eligible populations has reduced the out-of-pocket health payment burden in many of the countries but overall, there is a lack of access, availability and affordability for diagnostic-related services.

INTRODUCTION
The Lancet Commission on diagnostics provided compelling evidence that scarcity of diagnostic capacity and capability remains a challenge in low-income and middle-income countries (LMICs).1 The Commission estimated that nearly half of the world’s population has little to no access to diagnostics and highlighted the gap in access to diagnostic testing even for basic tests, particularly at the primary care level. It also emphasised the need for countries to include diagnostics as part of their journey towards universal health coverage (UHC). Another key finding was that public financing plays an important role in improving access: government-sponsored health insurance schemes are a key financing mechanism for UHC.2 A major recommendation of the Commission was that all countries develop their national diagnostics strategy, based on an integrated and tiered network, including an evidence-based national essential diagnostics list (NEDL), with a prioritised subset for UHC.

Health financing schemes are the main building blocks of the functional structure of a country’s health financing system through which health services are paid for and through which people can access healthcare.2,3 This paper follows the System of Health Accounts classification of healthcare financing schemes.3 These include government financing arrangements, compulsory health insurance and voluntary financing arrangements, as shown in table 1.

All schemes may not necessarily cover the total price of the included services and involve cost sharing through copayments, or caps on financial protection requiring out-of-pocket (OOP) payments. The ways in which health financing can support the inclusion of diagnostics in country government-sponsored health insurance schemes was not fully explored in the Lancet Commission on diagnostics.

In this paper, we build on the Commission’s analysis and fill this knowledge gap by investigating the extent to which diagnostics are included in government health insurance schemes in seven LMICs in...
WHAT IS ALREADY KNOWN ON THIS TOPIC

- Lack of access, availability and affordability for diagnostic-related services in low-income and middle-income countries (LMIC) is widely known. The Lancet Commission on Diagnostics estimated that nearly half of the world’s population has very little access to diagnostics, with lack of access particularly acute in primary care.

WHAT THIS STUDY ADDS

- Our study is the first to examine whether government-sponsored health benefit schemes include diagnostic-related services in seven Asian LMICs: Cambodia, India, Indonesia, Nepal, Pakistan, Philippines and Viet Nam. We show that none of the countries present a clear policy rationale or detailed information about which diagnostic-related services are covered. Only India has developed a national essential diagnostics list (NEDL).

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

We demonstrate ways in which countries can prioritise diagnostics in their health benefit packages, align with NEDLs and embed diagnostics for all as part of Universal Health Coverage. We make several recommendations:

- Government health benefit schemes should include diagnostics, drawing on appropriate population health information such as disease burden.
- Data should be collected about diagnostic usage, including on diagnostics provided through vertical programmes.
- Schemes should invest in knowledge and educational information to encourage population enrolment.
- Financing of diagnostics requires linkages to both public and private providers. Financial integration of vertical programmes, cross-subsidisation and setting reimbursement case rates for diagnostics could help to mitigate the high out-of-pocket payments patients currently face in these settings.

Asia—Cambodia, India, Indonesia, Nepal, Pakistan, Philippines and Viet Nam. We selected these countries because we wanted to understand varied approaches to the design of government-sponsored health insurance schemes in countries which have highly privatised health systems, and to include schemes with a range of maturity and population coverage. All seven countries have embarked on UHC agendas, and progress towards UHC is tracked as Sustainable Development Goal 3.8. In heavily privatised systems, the inclusion of diagnostics in government insurance schemes would help to reduce the OOP payments associated with testing. Collectively, the population of these seven countries is approximately 2.15 billion people, almost a quarter of the world’s population, making the design and performance of these schemes of substantial global health importance.

All seven countries are undergoing a health financing transition; this concept refers to a transition from a stage where total health spending was low and primarily OOP, to later stages where government health spending is higher and a higher proportion of funds are primarily pooled to purchase healthcare services. Pooling allows financial risk to be spread across the population, so no individual carries all the financial burden to pay for healthcare costs. In higher-income countries, where a higher proportion of funds are primary pooled, diagnostics are included in the benefit basket of government-sponsored schemes; for example, in Australia laboratory services account for 3% of total health expenditure compared with 10% in India.

Our work had four objectives:
1. To examine the benefit package of the government health insurance scheme for seven LMICs in Asia with substantial private sector involvement in healthcare.
2. To ascertain the population coverage of each government health insurance scheme.
3. To examine the mechanisms adopted to include diagnostics in each government health insurance scheme.
4. To identify ways to improve the benefit packages of the government health insurance schemes to support UHC.

In the paper, we defined diagnostics as pathology and laboratory medicine (PALM) and diagnostic imaging (DI) including at the point of care. A health financing template developed for this study supported information gathering; government sponsored schemes refer to both government financing and compulsory health insurance (online supplemental appendix 1). The search looked at the following aspects: scheme development, policy rationale, population coverage, financial coverage including copayments, caps and premiums, diagnostics included in the scheme, purchasing arrangements, performance of the scheme, access to diagnostics and alignment with vertical programmes.

We conducted a targeted literature review in seven countries: Cambodia, India, Indonesia, Nepal, Pakistan, Philippines and Viet Nam. The following databases were searched from 2012 to 2022 for literature relating to each

<table>
<thead>
<tr>
<th>Government financing</th>
<th>Compulsory health insurance schemes (predominantly social health insurance)</th>
<th>Voluntary financing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Set by law</td>
<td>Set by law defining eligibility</td>
<td>Includes voluntary health insurance schemes and household out-of-pocket payments</td>
</tr>
<tr>
<td>The benefit basket (services included in the scheme) is unremarkable (universal or eligibility for specific population groups)</td>
<td>Include services and rules for contributions (premiums) from or on behalf of the individual</td>
<td></td>
</tr>
<tr>
<td>Financing based primarily on domestic revenues</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Features of healthcare financing schemes

Bigio J, et al. BMJ Glob Health 2023;8:e012512. doi:10.1136/bmjgh-2023-012512
country’s health insurance scheme: PubMed, CINHAL, EBSCO. The search included PALM, DI, benefit package, health insurance, UHC coverage, health financing, health system (online supplemental appendix 1). Government and health ministry websites were searched for documents relating to government-sponsored health insurance schemes published in English. The websites of the following additional organisations were searched for relevant data on each of the seven countries: WHO, Partners for Health, Results for Development, World Bank, Institute for Health Metrics and Evaluation, Overseas Development Institute and Center for Global Development. Country coauthors supported the identification of relevant publications, including those not readily available in English.

The Lancet Commission on diagnostics used access to tests for diabetes, hypertension, HIV, tuberculosis (TB), hepatitis B in pregnant women and syphilis in pregnant women as a measure of diagnostic availability in an outpatient setting.\(^2\) We mapped these six priority conditions onto the country schemes to determine their inclusion in the benefit basket. Where schemes included treatment for a given disease but did not specify relevant diagnostics (eg, TB), we assumed the diagnostics were included.

**HEALTH FINANCING OVERVIEW**

Government sponsored health insurance schemes are in place in all seven countries but are at differing stages of development. The schemes in the Philippines and Viet Nam began in the 1990s, those in Cambodia and India in the 2000s and those in Indonesia, Nepal and Pakistan in the 2010s. All schemes are backed by legislation outlining the design of the benefit scheme service packages and eligibility requirements for coverage. The country’s entire population is eligible in Nepal, Philippines and Viet Nam, although registration rates vary from 21% in Nepal\(^8\) to 92% in Viet Nam.\(^9\) The remaining countries have hybrid systems, with insurance schemes in place for lower-income groups or those living in certain areas. The scheme in Cambodia is available to households identified as poor (24%),\(^10\) in India to households identified as poor or vulnerable (approximately 40%, with registration ongoing)\(^11\) and in Pakistan to all permanent residents of provinces and territories participating in the scheme.\(^12\) A summary of the key features of the financing of the schemes in each country is given in table 2 with country-specific details provided in online supplemental appendices 2 and 3.

All seven countries have highly privatised healthcare systems: government financing and compulsory health insurance together ranged from 27% in Nepal to 49% in Indonesia in 2019 (figure 1). OOP payments as a share of current health expenditure (CHE) ranged from 35% in Indonesia to 64% in Cambodia while government health expenditure as a share of gross domestic product (GDP) ranged from 0.9% in India to 2.3% in Vietnam in 2019 (figure 2). Figure 2 illustrates that the seven countries are at different stages of how they finance their healthcare system, from earlier stages where health spending is primarily OOP (eg, India), to later stages where health spending is higher and primarily pooled (eg, Viet Nam). The financing and delivery of vertical programmes often rely on external partners, ranging from 0.4% in the Philippines of CHE to 11.9% in Nepal (online supplemental appendix 3).

**SCHEME DESIGNS AND FINANCIAL COVERAGE**

The most recent published information on the benefit packages varied by country: Cambodia (2018), Nepal (2017), India (2019), Indonesia (2017), Pakistan (2021), Philippines (2020) and Viet Nam (2016). The seven schemes are organised differently with respect to the services included in the benefit basket, premiums, copayments and caps on usage. Cambodia\(^13\) and Nepal\(^14\) cover inpatient, outpatient and emergency care, and Cambodia additionally covers transportation costs and funeral expenses. India covers secondary and tertiary hospitalisation.\(^11\) Indonesia\(^15\)\(^16\) and the Philippines cover primary care, inpatient and outpatient care.\(^17\) Pakistan covers inpatient and emergency, but not outpatient care.\(^12\)\(^18\) Viet Nam covers inpatient and outpatient care.\(^19\)\(^21\)

Most of the schemes are organised into benefit packages covering the treatment and management of different groups of conditions. Some schemes, such as those in Nepal\(^22\)\(^23\) and Pakistan,\(^24\) strictly cover only specifically listed conditions whereas others, such as the scheme in the Philippines, have broader packages such as ‘General Out-Patient Consultation’.\(^25\) Cambodia\(^13\)\(^19\) and Indonesia\(^26\) have no caps on usage. India has a cap of INR500 000 (US$6074) per family per year,\(^11\) Nepal has a cap of NPR100 000 (US$806) per family per year, with extra allowances for certain population groups,\(^14\)\(^27\) Pakistan has a cap of Rs1 000 000 (US$16 000) per family per year, with an extra allowance to cover certain diseases,\(^24\) the Philippines has a cap of PHP32 000 (US$600),\(^28\) and Viet Nam has a cap for each episode equivalent to the country minimum salary over 40 months.\(^19\) Beyond the caps, payment is OOP.

Cambodia, India and Pakistan do not require the payment of premiums by the beneficiaries. In Indonesia, informal workers must enrol themselves and pay a monthly premium while formal workers are registered by their employers.\(^15\) In Nepal, a family of five must pay NPR3500 (US$28) per year, with an extra NPR700 (US$6) per additional family member, with subsidies for certain groups.\(^27\) In the Philippines, the premium is 4% of monthly salaries up to a cap\(^28\)\(^29\) while in Viet Nam it is 4.5% of basic monthly salary,\(^19\)\(^29\) and both countries have subsidies for certain groups.\(^30\) Viet Nam requires copayments, set at 20% of incurred costs except for subsidised groups including those with at least 5 years of participation and an annual total payment amount capped at 6 months of basic monthly salary.\(^30\)
<table>
<thead>
<tr>
<th>Country</th>
<th>Scheme name and year of establishment</th>
<th>Eligible population</th>
<th>Eligible population coverage (% eligible population)</th>
<th>Scheme design and coverage</th>
<th>Copayments, premiums and caps</th>
<th>Purchasing arrangements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambodia</td>
<td>Health Equity Fund (HEF) (2000)</td>
<td>Individuals identified in the IDPoor registry and certain categories of informal workers, exclusion for people who inject drugs</td>
<td>24% (2020)</td>
<td>Preventive or curative care (outpatient, inpatient or in emergencies). Transportation costs to referral hospitals and funeral expenses for inpatient deaths are included with no cost ceiling</td>
<td>No copayments, premiums or caps. OOP payment</td>
<td>Diagnostics and laboratory testing are implicitly included in the service packages. Reimbursement is based on the number of service packages provided to HEF beneficiaries and deductions are made for any penalties associated with the submission of false claims or incomplete documentation</td>
</tr>
<tr>
<td>India</td>
<td>Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (2018)</td>
<td>Households identified as poor or vulnerable (~40%)</td>
<td>32% (2021), 164 million e-cards issued</td>
<td>Cashless unremarkable scheme covering secondary and tertiary hospitalisation at public and private empanelled hospitals up to a cost ceiling</td>
<td>Cap of INR500 000 (US$674) per family per year, then OOP payment. No copayments or premiums</td>
<td>53% of participating hospitals are public, with the remainder private. States can either purchase services through an insurance company, purchase directly by the state-owned agency or a mixture of both</td>
</tr>
<tr>
<td>Indonesia</td>
<td>Jaminan Kesehatan Nasional (2014, on consolidation of previous schemes)</td>
<td>Country population, with some exclusions</td>
<td>83% (2019)</td>
<td>Primary care, inpatient and outpatient care included with no cost ceiling</td>
<td>Those formally working are registered by their employers while informal workers must enrol themselves and pay a monthly premium. No copayments or caps</td>
<td>The scheme contracts with all public and most private providers, including public hospitals, private clinics and individual private physicians</td>
</tr>
<tr>
<td>Nepal</td>
<td>Health Insurance Board (2016)</td>
<td>Country population (100%)</td>
<td>20% (2022)</td>
<td>Outpatient, inpatient and emergency care included up to a cost ceiling</td>
<td>Family premium of NPR3500 (US$28) per year with subsidies for certain groups. Cap of NPR100 000 (US$806) per family per year but can be higher for certain groups, then OOP payment</td>
<td>Private laboratories are not yet integrated into the scheme, but private medical colleges, private nursing homes, and community-based healthcare facilities are</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Sehat Sahulat Programme from 2018 (regional schemes between 2014 and 2018)</td>
<td>Full population in most provinces and territories</td>
<td>89% (2022)</td>
<td>Cashless unremarkable scheme covering inpatient and emergency, but not outpatient. Health services in empanelled hospitals up to a cost ceiling</td>
<td>No copayments or premiums. Cap of Rs1000 000 (US$13840) per family per year for priority diseases with an extra Rs60 000 (US$777) for secondary diseases, then OOP payment</td>
<td>The scheme contracts directly with empanelled hospitals (public or private)</td>
</tr>
<tr>
<td>Philippines</td>
<td>Philippine Health Insurance Corporation (PhilHealth) (1995)</td>
<td>Country population (100%)</td>
<td>86% (2021)</td>
<td>Benefit packages (primary care, outpatient, and inpatient) in accredited or contracted public or private facilities up to a cost ceiling</td>
<td>Premium of 4% of monthly salary up to a maximum of PHP 3200 (US$61) for formal employees. Means-tested premium subsidies for those informally employed. Copayment required for non-basic hospital accommodation but not for basic or ward accommodation. Cap of PHP 32 000 (US$600), then OOP payment</td>
<td>Health facilities can put in place a memorandum of understanding with other health facilities to provide diagnostic services when not available in their own facility</td>
</tr>
</tbody>
</table>

Continued
PROVISION OF DIAGNOSTICS IN THE SCHEMES

Of the seven countries, only India has developed an NEDL; it has guidelines on the use of diagnostics in the treatment packages in the scheme. However, it is unclear to what extent the Indian NEDL has informed the availability of diagnostics in their Free Diagnostics Service Initiative under the National Health Mission or the Pradhan Mantri Jan Arogya Yojana (PM-JAY) insurance scheme. Viet Nam is in the process of developing its NEDL but has not yet completed the project. In some countries, including Pakistan and the Philippines, the rationale for the inclusion of certain medical conditions in the scheme coverage is explicitly described based on conditions with substantial burdens or that are common causes of catastrophic health costs in the country. However, descriptions of the rationale behind the inclusion of the specific diagnostics within the schemes are generally poor or non-existent across countries.

The schemes cover diagnostics in all settings for which they cover care. All schemes, therefore, cover at least some inpatient diagnostics, but many also include diagnostics in primary care and outpatient hospital settings. India is the exception where diagnostics in primary care are not linked to the scheme and the availability of diagnostics

<table>
<thead>
<tr>
<th>Country</th>
<th>Scheme name and year of establishment</th>
<th>Eligible population</th>
<th>Eligible population coverage (% of eligible population)</th>
<th>Scheme design and coverage</th>
<th>Copayments, premiums and caps</th>
<th>Purchasing arrangements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viet Nam</td>
<td>Social Health Insurance (1992)</td>
<td>Country population (100%)</td>
<td>92% (2022)</td>
<td>Inpatient and outpatient hospital care in public and government-approved private facilities and other health facilities, as well as transportation services in poor and mountainous areas, included up to a cost ceiling</td>
<td>Premium of 4.5% of basic monthly salary with subsidies for certain groups. Copayments at 20% except for fully subsidised groups. Copayment ceiling equivalent to 6 months' basic salary for those with 5 years of continuous membership. Cap in place for high cost technical services</td>
<td>Contracting in place with both public and private providers, though public sector predominates. Unregistered facilities can be reimbursed if a reference letter from a registered facility is provided before patient transfer</td>
</tr>
</tbody>
</table>

Note: all dollar amounts are in US dollars.

LMICs, low-income and middle-income countries; OOP, out of pocket.

### Figure 1
Sources of health financing schemes by country. Data from Global Health Expenditure Database (2019).
for outpatient care is not made explicit. Descriptions of available diagnostics from most countries are vague and either list the medical conditions for which diagnostics are available without specifying the exact diagnostic type or brand or do not list the available diagnostics at all. Procedures or treatments listed in the schemes implicitly include diagnostics as seen in India, Indonesia, Pakistan and the Philippines. Nepal, specifies 125 laboratory tests and 77 radiological and other diagnostic services, though official documents do not distinguish the levels of the health system at which different diagnostics are available.35 Pakistan includes diagnostics for inpatient services but explicitly excludes admissions specifically for the purpose of diagnosis.

Purchasing and Reimbursement Providers for Diagnostics

Legislative tools are in place in all the countries for purchasing, and to reimburse providers. In most countries, contracts include both public and private providers. In Nepal, private laboratories are not yet integrated into the scheme.14 In Indonesia, all public and most private providers are contracted.26 In the Philippines, an agreement can be put in place with another health facility to provide diagnostics when not available in the facility in question. India is moving towards putting in place a hub and spoke model for accessing diagnostics.

In Viet Nam, unregistered providers can be reimbursed if a reference letter from a registered facility is provided before patient transfer.36

Availability of Lancet Commission Tracer Conditions

To examine the state of diagnostics access globally, the Lancet Commission identified six priority conditions: diabetes, hypertension, HIV, TB, hepatitis B in pregnant women and syphilis in pregnant women.1

The seven countries did not all explicitly include diagnostics for these priority conditions in their government schemes (table 3). In Cambodia, diabetes, HIV and TB, syphilis are included, though it is unclear if they are provided to pregnant women; hypertension and hepatitis B for pregnant women were not specified.13 In India, diabetes, hypertension, HIV, TB, hepatitis B are included for inpatients, but syphilis is not mentioned. In Nepal, diabetes and hypertension are included; those for hepatitis B and syphilis are also included, though it is unclear if they are provided to pregnant women; HIV and TB are provided through vertical programmes outside the scheme.35 In Pakistan only complications requiring admission are included, but these include diagnostics for diabetes, hypertension, HIV, TB and hepatitis B. Most diagnostic provision in Pakistan is supported by donors such as the Global Fund to Fight AIDS, Tuberculosis and Malaria. Sexually transmitted diseases (STDs) are generally excluded including syphilis.24 In the Philippines,
diabetes, hypertension, HIV and TB are included. Hepatitis B and syphilis are also included, though it is unclear if they are provided to pregnant women. In Viet Nam, diabetes, hypertension, hepatitis B and syphilis are included for all, including pregnant women. HIV and TB are provided through vertical programmes. There are no details about the tracer conditions in the benefit package for Indonesia.

**VERTICAL ALIGNMENT**

In Nepal, the vertical programme of TB is integrated into the government sponsored health insurance scheme with similar plans for TB in Viet Nam.37 In Nepal and Viet Nam, HIV testing are provided through vertical programmes integrated into the government sponsored health insurance schemes. It remains unclear the extent to which vertical alignment of programmes are working in practice with government sponsored health insurance schemes in the remaining six countries. In India, there are national programmes (e.g. for cancer and dialysis) but it is unclear if these programmes are aligned with the PM-JAY.

**SCHEME PERFORMANCE**

Despite the range of caps from US$600 in the Philippines to US$6074 in India (table 2), the evidence on the performance of the schemes with respect to accessing diagnostics is mixed. Philippines is the only country to publicly share data on diagnostics claims, which accounted for 2% of total claims in 2021, but this may not reflect all diagnostic activity, some of which could be included under other claim categories. Despite efforts to expand insurance coverage in many of the countries, more work is needed—for example, Nepal faces challenges to prevent enrolled families from dropping out of the scheme.37 38 Changes to OOP expenditure with the introduction of these schemes is mixed. Indonesia experienced a drop in the overall share of OOP payments, but its progressivity has declined, suggesting that the poorest citizens are not making full use of the financial protection provided by the scheme.39 Cambodia’s scheme is pro-poor with the lower-income individuals paying less and receiving more PHC spending than higher-income individuals.40 41 India42 and Viet Nam43 44 still have high levels of OOP payment. In India, this may involve paying upfront while waiting for reimbursement, or patients visiting a private hospital where they are required to pay for the packages not covered. Covid-related testing and hospitalisation show large differences between public and private sector facilities in India. Patients forego tests because of the cost, but there is no data to show what proportion of the population is affected. The Lancet Commission tracer conditions, distribution

<table>
<thead>
<tr>
<th>Country</th>
<th>NEDL in place</th>
<th>Does the scheme explicitly include diagnostics?</th>
<th>Lancet Commission tracer conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cambodia</td>
<td>No</td>
<td>Yes</td>
<td>Primary care and hospital settings not specified; Diabetes, HIV and TB, those for syphilis are also included, though it is unclear if they are provided to pregnant women. Hypertension and hepatitis B for pregnant women not specified but may be included in general service packages covering investigations as indicated by consultation.</td>
</tr>
<tr>
<td>India</td>
<td>Yes</td>
<td>Yes</td>
<td>Diabetes, hypertension, HIV, TB; hepatitis B included. Syphilis is not mentioned.</td>
</tr>
<tr>
<td>Indonesia</td>
<td>No</td>
<td>Yes</td>
<td>Yes; Diabetes, hypertension, HIV; TB; hepatitis B included. Syphilis is not mentioned.</td>
</tr>
<tr>
<td>Nepal</td>
<td>No</td>
<td>Yes</td>
<td>Not specified in which settings diagnostics are available; Diabetes and hypertension are included; those for hepatitis B and syphilis are also included, though it is unclear if they are provided to pregnant women. HIV and TB are provided through vertical programmes.</td>
</tr>
<tr>
<td>Pakistan</td>
<td>No</td>
<td>Yes</td>
<td>Yes; Complications requiring admission includes diagnostics for diabetes hypertension, HIV, TB and hepatitis B. HIV is included, STDs are generally excluded including syphilis.</td>
</tr>
<tr>
<td>Philippines</td>
<td>No</td>
<td>Yes</td>
<td>Yes; Diabetes, hypertension, HIV and TB are included. Hepatitis B and syphilis are also included, though it is unclear if they are provided to pregnant women.</td>
</tr>
<tr>
<td>Viet Nam</td>
<td>No</td>
<td>Yes</td>
<td>Early diagnosis for some diseases and prenatal tests specified in primary, outpatient and inpatient care; Diabetes, hypertension, hepatitis B and syphilis are included for all, including pregnant women. HIV and TB are provided through vertical programmes.</td>
</tr>
</tbody>
</table>

HIV, human immunodeficiency virus; LMICs, low-income and middle-income countries; NEDL, national essential diagnostics list; STDs, sexually transmitted diseases; TB, tuberculosis.

**Table 3** Key features of the inclusion of diagnostics in government-sponsored health insurance schemes in seven LMICs in Asia
and availability of diagnostics remains a challenge in all seven countries, reflecting a global trend reported in the Lancet Commission.\(^1\)

**CONCLUSION**

In conclusion, there is considerable heterogeneity in the country approaches to diagnostics in the government-sponsored health insurance schemes. The level of detail on the availability of diagnostics in the benefit packages varies, including for the six Lancet tracer conditions. A clear policy rationale on which diagnostics are included or not included is absent from all schemes. Insurance expansion across the countries has mitigated some of the OOP burden, but the overall lack of access, availability and affordability for diagnostics-related services remains a problem.

Our analysis has several limitations. Our study only included Asian countries with a focus on seven countries, to capture differences in scheme development within highly privatised health systems. Our targeted review focused on the most relevant evidence and was not systematic in design. Furthermore, the analysis is based on available information on the benefit packages to date and will not have captured current changes underway and so we are unable to verify the published information in the field, although we did seek input from experts from most of the countries and include them as co-authors. The referenced publications were predominantly in English and so is not exhaustive of publications in each country’s native language.

The focus of this work was on diagnostic inclusion in the benefits package. It did not study links to other benefit schemes (eg, social benefits) that may be accessible to eligible populations and their direct or indirect contribution towards health financing, or other large schemes in operation (eg, the Employees’ State Insurance scheme in India). We did not examine links to payment systems and incentives, including bundling and contractual arrangements. The intersection between insurance, diagnostics and how payment systems function is an important policy area worthy of future work but was outside the scope of this analysis.

Based on our findings, we set out the following recommendations. First, all government-funded health insurance schemes should explicitly include diagnostics and specify the range of available diagnostics in different settings, with that range determined by the disease profile in each country. Second, since only one of seven countries has developed a national essential diagnostics list, the development of NEDLs in all countries will bring greater attention to diagnostics and promote their inclusion and alignment with government-sponsored insurance schemes. Third, data should be collected and published on the use of diagnostics in government-sponsored schemes, including by regularly identifying high cost, high burden diseases which require specific diagnostics. Fourth, data should also be collected on the use of diagnostics provided through vertical programmes outside the government-sponsored schemes (including those accessible through the private sector). Fifth, systematic data collection on health financing for diagnostics is necessary in each country including pricing, reimbursement and purchasing arrangements. Sixth, there are knowledge gaps in the uptake of the schemes among the eligible populations, which would require a range of stakeholders working together to support and improve its uptake. Seventh, supportive financing policies should be better aligned with the inclusion of diagnostics around domestic resource mobilisation and innovative financing. The financing of diagnostics requires linkages to the wider health system between public and private providers including how to support diagnostics found in vertical delivery programmes that sit outside the government sponsored schemes. This could include financial integration of vertical programmes, cross-subsidisation and setting reimbursement case rates for diagnostics as part of these services. Finally, a country’s UHC strategy should draw on its own NEDL, reflected in the benefit package, that contains clear criteria such as clinical guidelines and cost-effectiveness analyses.

Our study identifies broader policy implications in taking a diagnostics-wide lens across a package of care that could be valuable to countries (eg, standardisation of care, contract negotiations) to improve consistency in care, equity and efficiency in health systems. The provision of diagnostics is vital for successfully introducing UHC. The UHC Compendium\(^49\) and the Global Atlas of Medical Devices\(^50\) aim to inform investment decisions around the benefits packages by drawing on the EDL. Internationally, the WHO Executive Board decided to recommend a resolution on strengthening diagnostic capacity at the 76th World Health Assembly\(^51\). UHC offers the opportunity to rethink how to bring diagnostics more formally into the government sponsored health insurance schemes, so that diagnostics are embedded and prioritised as part of the broader country’s health system response and progress towards to UHC.

**Author affiliations**

1 Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada
2 McGill International TB Centre, Montréal, Quebec, Canada
3 FIND, Geneva, Switzerland
4 Department of Epidemiology & Biostats, McGill University, Montréal, Quebec, Canada
5 Research Center for Care and Control of Infectious Diseases (RC3ID), Universitas Padjadjaran, Bandung, Jawa Barat, Indonesia
6 Friends for International TB Relief, Ho Chi Minh City, Vietnam
7 Interactive Research & Development, Singapore
8 Family Health International (FHI360), Manila, Philippines
9 Woolcock Institute of Medical Research, Hanover, Viet Nam
10 Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia
11 World Health Organization, Lahore, Pakistan
12 School of Epidemiology and Public Health, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
13 Faculty of Management Studies, University of Delhi, New Delhi, India
REFERENCES


38. BSN and World Health Organization. national health insurance scheme among the households of ilkam district, Nepal. Health for the Millions 2012:1–70.


Bigio J, et al. BMJ Glob Health 2023;8:e012512. doi:10.1136/bmjgh-2023-012512


Appendix 1
Health Financing Template

1. Health insurance scheme
   a. Population coverage: eligibility criteria – what are they?
   b. Benefit package: what diagnostics are included, and for which conditions (e.g., health visits, hospitalisation related services)? Is there a primary care component, and whether preventive and promotive services are included? Are diagnostics included primarily with vertical disease programs?

2. Financial protection mechanisms: especially with regards to community-based service delivery
   a. What is in place for those not eligible for insurance schemes and require diagnostics?
   b. If not provided, but planned to be provided and by whom and are they actually provided?

3. Purchasing mechanism:
   a. Can the insurance schemes contract with civil society/community-based organisations or private laboratories to provide diagnostics? Any covered by external partners? Accreditation and workforce requirements?

4. Other financing streams/cross-subsidisation:
   a. Is there collaboration with other financing streams/institutions in the country to finance diagnostics?

5. Role of external partners:
   a. Is there work underway to integrate any vertical programmes of diagnostics into UHC?

6. Scheme Innovations
   a. Initiatives implemented? Learning from others? Initiatives to improve performance, e.g., performance-based financing, legislation

7. Performance of the insurance scheme
   a. What challenges exist in the country to integrate diagnostics into SHI to support UHC?
   b. How might better performance of the insurance scheme be incentivised?
   c. Are there actors that can be better leveraged/catalysed?
   d. Is accountability an issue? What mechanism(s) could improve accountability?
   e. Is coordination an issue? What mechanism(s) could improve coordination?
   f. Is program oversight/understanding an issue? How might better oversight be implemented?

8. Information/Data on diagnostics:
   a. Insurance Scheme breakdown:
      i. Population eligible for insurance coverage (national, sub-national)
      ii. Claims information of access to diagnostics (national, sub-national)
      iii. Performance reports of facilities or secondary information
   b. Financing map
      i. Points of resource mobilisation (insurance contributions, taxes, etc.)
      ii. Pools – which actors hold the funds
      iii. Purchasing – who pays (insurance, MoH, sub-national governments, etc.)
   c. Delivery
      i. Points of delivery (e.g., care setting)
      ii. Provider payment mechanisms
      iii. Financial/non-financial incentives for delivery
      iv. Reporting and monitoring access of diagnostics (reliability of data, collector and who they report to)
<table>
<thead>
<tr>
<th>SEARCH TERMS:</th>
<th>And benefit package</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic imaging (DI), or diagnostics AND</td>
<td>And Health insurance</td>
</tr>
<tr>
<td></td>
<td>And UHC coverage</td>
</tr>
<tr>
<td></td>
<td>And Health Financing</td>
</tr>
<tr>
<td></td>
<td>And Health system</td>
</tr>
<tr>
<td>Pathology and laboratory medicine (PALM) or laboratory medicine AND</td>
<td>And benefit package</td>
</tr>
<tr>
<td></td>
<td>And Health insurance</td>
</tr>
<tr>
<td></td>
<td>And UHC coverage</td>
</tr>
<tr>
<td></td>
<td>And Health Financing</td>
</tr>
<tr>
<td></td>
<td>And Health system</td>
</tr>
</tbody>
</table>
Appendix 2

Cambodia

Scheme development: The Health Equity Fund (HEF) was started in 2000 in two districts and by 2015 provided national coverage (1). Households identified as poor through the triennial national IDPoor survey by the Ministry of Planning (2, 3) are eligible and receive an Equity Card. Individuals who become impoverished between rounds of IDPoor can be post-identified as poor at public health facilities and receive a Priority Access Card (4). With either card, clients can receive free preventive or curative care as outpatients or inpatients or in emergencies, transportation costs to referral hospitals and funeral expenses for inpatient deaths (5). ID cards are valid until the next round of IDPoor enrolment. Budget is jointly funded by the Government of Cambodia (71% contribution in 2019) and external donors through a pooled funding mechanism, with the government planning to increase funding to 100% by 2025 (6).

Policy rationale: Although coverage for diagnosis is included in the service packages, the range of specific diagnostics covered is not specified and no criteria for their inclusion are mentioned in the relevant documentation (38).

Population coverage: As of the 2018-2020 survey, 3.2 million people (24%) were identified as poor and so were eligible for HEF (7). The number of people post-identified as poor at health facilities is unclear.

Financial coverage: Unlimited access to the full range of services at each level of the health system (5). Non-medical benefits include reimbursement for transportation costs, food allowances and funeral support.

Co-payments or premiums: None.

Diagnostics included in the scheme: In both primary care and in hospital settings, all types of available diagnostics are covered but the range of available diagnostics is not specified (5, 8).

Lancet Commission tracer conditions: Diagnostics for diabetes, HIV and TB are included; those for syphilis are also included, though it is unclear if they are provided to pregnant women. Diagnostics for hypertension and hepatitis B for pregnant women are not specified but may be included in general service packages covering investigations as indicated by consultation (5).

Purchasing arrangements: The HEF reimburses facilities using payment rates associated with each service package, which are set by the HEF (5).

Alignment with vertical programs: The National Malaria Program is a standalone vertical government-funded programme that includes diagnostics and is not integrated with the HEF (9).

Performance of the scheme: In 2017, HEF-funded households had decreased out-of-pocket expenditure per illness compared with non-HEF households (10). A 2019 study found that the implementation of HEF was associated with increased utilisation of primary and secondary care services by the poor (11). A benefit incidence analysis from 2019 suggested that health spending in primary care is distributed in favour of the poor, with 32% of PHC spending going to the poorest population quintile (12).

Access to diagnostics: No published data is available on access to diagnostics through HEF.

India

Scheme development: The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) was launched in 2018, replacing Rashtyira Swasthya Bima Yojana (RSBY), the previous government-funded scheme that primarily focussed on migrant labour (13), which enrolled 41 million families but did not significantly reduce...
out-of-pocket payments (14-16). Under PM-JAY, households identified as poor or vulnerable in the Socio-
Economic Case Census 2011 (approximately 40% of the population or 500 million people) are eligible. It is a
cashless non-contributory scheme providing e-cards which allow eligible households to receive secondary and
tertiary hospitalisation at public and private empanelled hospitals anywhere in India up to a cost ceiling (13).
Financing comes from a combination of federal and provincial governments. Tariffs for each benefit package
are set by the National Health Authority (17).

Policy rationale: PM-JAY aims to support progression to UHC by covering the large uninsured poor population
of India. States can extend the benefit package and population coverage at their discretion. In 2019, India
became the first country to publish a National EDL (NEDL), based on the WHO EDL (18), but it is not yet clear
how the NEDL relates to diagnostics available through PM-JAY.

Population coverage: By 2021, 164 million e-cards had been issued (32%) (19).

Financial coverage: Up to INR 500,000 ($6074) per family per year (13).

Co-payments or premiums: Once the annual cap is exceeded, patients must pay OOP (17). India has one of the
highest rates of OOP expenditure in the world, accounting for two-thirds of total health expenditure, with
diagnostics accounting for 10% of OOP payment (20).

Diagnostics included in the scheme: PM-JAY covers up to three days pre-hospitalisation and 15 days post-
hospitalization expenses including diagnostics. Hospital expenses incurred outside this period primarily for
diagnostic purposes are not included (17). Primary care and outpatient services are not included. A full list of
the diagnostics available under PM-JAY is not available, and while some are listed (e.g., HIV, TB, hepatitis), and
it is unclear how diagnostics in the scheme correspond to the NEDL.

Lancet Commission tracer conditions: All included in the NEDL (21) but unclear if widely available under PM- JAY.

Purchasing arrangements: Services are reimbursed via 920 fixed-rate packages split into 1,669 procedures in
26 specialties with a provision for 77 additional procedures (17). In 2020-21, 53% of participating hospitals
were public, with the rest private (19). States either purchase services directly, utilise insurance companies, or
a mixture of both (22).

Alignment with vertical programs: No details available.

Performance of the scheme: Studies performed in three states suggest that PM-JAY has not prevented OOP
expenditure completely for hospital care that should be covered under the program. Additionally, weak
regulation allows private hospitals to seek co-payments or upfront payments not allowed in the scheme, while
the hospital awaits claim reimbursement, which occurs more slowly than is proposed in guidelines (16, 23).

Access to diagnostics: No published data is available on access to diagnostics through PM-JAY. To prevent
abuse, certain service packages are only available in private hospitals if patients have been referred from
public hospitals (23). A pilot survey performed shortly before the introduction of the NEDL and PM-JAY
identified major gaps in access to essential diagnostics in three Indian states (24).

Indonesia

Scheme development: The Jaminan Kesehatan Nasional (JKN) was established in 2014 after the consolidation
of earlier schemes. All individuals are eligible for primary care, inpatient and outpatient care (25, 26). Those
formally working are registered by their employers while informal workers must enrol themselves and pay a
monthly contribution fee to receive a membership card (25). The poor and near-poor have their contributions
partially or fully subsidized by national and district authorities (25, 27). Financing comes from government
budget allocations, loans from the World Bank (28) and premiums received.
**Policy rationale:** JKN is the major pillar in the government’s progression towards UHC and covers most of the health service delivery landscape, including diagnostics (29). However, no criteria for the inclusion of diagnostics are mentioned in the relevant documentation.

**Population coverage:** In 2019, 83% of the population was covered (29, 30).

**Financial coverage:** Unlimited access with no cap (29).

**Co-payments or premiums:** No co-payments. A regulation was introduced in 2018 to allow co-payments for some services but these have not yet been defined or implemented (29).

**Diagnostics included in the scheme:** The benefit package includes diagnostics offered in primary, outpatient and inpatient settings (26). The full list of available diagnostics is not available.

**Lancet Commission tracer conditions:** No details available.

**Purchasing arrangements:** The scheme contracts with all public providers and most private providers, including private hospitals, clinics and individual clinicians (29).

**Alignment with vertical programs:** No details available.

**Performance of the scheme:** During the scheme expansion between 2014 and 2019, population coverage improved from 53% to 83%, OOP expenditure as a share total health expenditure fell from 53% to 32% (29). However, the poorest quintile’s share of OOP payments remained constant, suggesting that the poorest citizens are not making full use of the financial protection provided by JKN (27).

**Access to diagnostics:** Little published data is available on access to diagnostics through JKN, though primary care clinics often lack basic diagnostics, particularly in remote areas (29).

### Nepal

**Scheme development:** The Health Insurance Program of Nepal, currently managed by the Health Insurance Board (HIB) of the Government of Nepal, started in 2016 in three districts and now covers all 77 districts of the country (31, 32). All citizens are eligible. It is a cashless system requiring annual membership fees. With an ID card, members can receive outpatient, inpatient and emergency care up to a cost ceiling (33). Financing comes from government budget allocations and premiums paid by enrollees (34, 35).

**Policy rationale:** Although numerous diagnostics are included in the benefit packages, no criteria for their inclusion are mentioned in the relevant documentation (36).

**Population coverage:** As of April 2022, 5.3 million people (20%) were enrolled in HIB, up from 15% in 2021 (32). Coverage varies and in half of the provinces is less than 10%.

**Financial coverage:** Benefit packages are available at public and contracted private PHC centres and registered hospitals up to an annual limit of NPR 100,000 ($806) for a family of five, with an extra NPR 20,000 ($161) per additional family member up to a maximum of NPR 200,000 ($1,611). People aged >70 years are eligible individually for an additional NPR 100,000 annually; up to NPR 100,000 annually is also available for members suffering from eight specified diseases: cancer, cardiovascular disease, renal failure, head and spinal injury, sickle cell anaemia, Parkinson’s disease and Alzheimer’s disease (33, 35). Costs for each included service are set by the Government of Nepal (36, 37).

**Co-payments or premiums:** A family of five must pay NPR 3,500 ($28) per year, with an extra NPR 700 ($6) per additional family member. 100% subsidy for: ultra-poor families certified by the local government, people aged >70 years, families of patients with HIV, MDR-TB, leprosy, or those who are severely disabled. A 50% subsidy is in place for families of female community health volunteers. (35).
Diagnostics included in the scheme: HIB covers 152 laboratory tests and 72 radiological and other diagnostic services, though official documents do not distinguish the levels of the health system at which different diagnostics are available (38, 39).

*Lancet* Commission tracer conditions: Diagnostics for diabetes and hypertension are included; those for hepatitis B and syphilis are also included, though it is unclear if they are provided to pregnant women. Those for HIV and TB are provided through vertical programs (38).

Purchasing arrangements. HIB contractual arrangements can include private medical colleges, private nursing homes, and community-based health care facilities, though these have not widely been put into place.

Alignment with vertical programs: Diagnostics for visceral leishmaniasis, malaria, HIV, TB, influenza, leprosy, maternal and child health and family planning are provided free through vertical programs which have been integrated into PHC and are not provided through HIB for reimbursement (38).

Performance of the scheme: Enrolment remains low, with high dropout rates commonly attributed to a lack of drugs, unfriendly service provider behaviour and a preference towards private clinics (35, 40). No breakdown on claims and reimbursements for diagnostics is publicly available.

Access to diagnostics: No published data is available on access to diagnostics through HIB but access to specialised diagnostics is likely to be limited because private diagnostic facilities are not yet integrated into the scheme.

Notes: Citizens seeking foreign employment, who often travel alone, need to submit proof of enrolment of their family in HIB, ensuring the family retains access while they are abroad.

**Pakistan**

Scheme development: The Sehat Sahulat Program (SSP) was established in a single province in 2015, with the Prime Minister Heath Insurance Scheme in place in other regions between 2015-2018 (41), and has since expanded stepwise through most provinces and territories (42). Initially only families earning less than $2 per day were covered (41) but this later expanded to include all permanent residents of participating provinces and territories (42). It is a cashless non-contributory scheme providing ID cards which allow free access to inpatient and emergency, but not outpatient, health services in so-called empanelled hospitals up to a cost ceiling (42, 43). Financing comes from a combination of federal and provincial governments.

Policy rationale: The SSP aims to protect against catastrophic inpatient health expenditure as part of Pakistan’s plan for UHC (44). The benefit package covers select high cost and high burden diseases. No criteria for the inclusion of diagnostics are mentioned in the relevant documentation.

Population coverage: 207 million (89%) as of 2022 after the scheme was extended to all of the population with a national ID card, although uptake has been low in Baluchistan and Sindh provinces (45, 46).

Financial coverage: Rs 300,000 ($1387) per family per year for priority diseases and Rs 60,000 ($277) per family per year for secondary diseases (44). Additional coverage up to the same amount for both categories is available for life saving or stabilising treatment, for all maternity and maternity-related services and for continuing treatment related to a specific admission if the limit is exceeded during that admission (43).

Co-payments or premiums: Reserve funds are available for treatments once the financial limits are met for renal dialysis and transplants, oncology, neuro surgical, cardiology, rheumatology, while national steering committee approval is required for other treatments (30). The most recent estimate from 2019 puts OOP at more than half or 54% of current health expenditure (47). Older data from the 2017/18 OOP Health Expenditure Survey reported that almost 75% of total OOP expenditure were incurred on outpatient services, while inpatient care was 20% (48).
Diagnosics included in the scheme: Primary care services are not included in the program (42) and admission to hospital primarily for diagnostic purposes is excluded (49). No information on diagnostics found from the Government of Pakistan but the Government of Punjab province states that lab tests and other diagnostics are covered but does not specify which in English (50).

Lancet Commission tracer conditions: Syphilis is excluded. Hospitalisation required for the treatment of diabetes, hypertension, HIV, TB and hepatitis B are included, but it is unclear whether this includes diagnostics (44).

Purchasing arrangements: Costs for each service are set by the Government of Pakistan (41).

Alignment with vertical programs: No information available.

Performance of the scheme: The SSP has spread rapidly across Pakistan, which is an important milestone towards UHC (41). However, one analysis found that OOP payments and catastrophic health expenditure increased between 2015 and 2018 (51). A limitation of SSP is that the cost caps for treatment set by the government are incompatible with those charged by some private hospitals, resulting in patients being asked to pay the difference out-of-pocket (41). An actuarial analysis conducted in 2019 suggested that the future financial sustainability of SSP could require increasing the premium provided per family (52). Not all hospitals are empanelled in the scheme, restricting provision of services with variation across the country.

Access to diagnostics: No published data is available on access to diagnostics through SSP.

Philippines

Scheme development: The Philippine Health Insurance Corporation (PhilHealth) was created in 1995 and expanded in 2019 so that all citizens are automatically eligible for the program (53). Financing comes from government budget allocations and premiums paid by registered members.

Policy rationale: In June 2021, the Department of Health announced the aim of creating a Philippine Essential Medical Device List to guide procurement of diagnostics and other devices and guide the costing and development of PhilHealth benefit packages (54). This has not yet occurred and no criteria for the inclusion of diagnostics are mentioned in the relevant documentation.

Population coverage: As of June 2021, 94.8 million people (86%) were registered members or their dependents listed in the PhilHealth database (55).

Financial coverage: Annual cap of PHP 32,000 ($600). Benefit packages are available for primary care and inpatient and outpatient services in accredited or contracted public or private facilities (56). Each included service has a published case rate, set by PhilHealth, which is subtracted from the payments required by patients (57, 58). Services beyond these case rates, or those not covered by PhilHealth, are paid out of pocket. A No Balance Billing provision prevents accredited hospitals from charging poor patients more than the case rates for each service. Diagnostic tests required for inpatient treatment but supplied by providers outside the hospital are also covered (59, 60).

Co-payments or premiums: For those formally employed, the monthly PhilHealth premium in 2022 is 4% of their basic monthly salary up to a maximum of PHP 3,200 ($61), increasing by 2025 to 5% with a maximum of PHP 5,000 ($95) (61, 62). Those informally employed can qualify for means-tested subsidies for the premiums. Co-payment is not required for basic or ward accommodation but is required for non-basic accommodation (63).

Diagnosics included in the scheme: The primary care benefit package covers CBC, urinalysis, fecalysis, sputum microscopy, fecal occult blood, pap smear, HbA1C, fasting blood sugar, oral glucose tolerance test, lipid profile, creatinine, ECG and CXR (64, 65). However, PhilHealth PHC also includes facilities with inpatient beds for stays...
of 1-3 days (66) and the medical benefit package for PHC covers diagnostics for a broad range of medical conditions based on ICD-10 codes (57).

The benefit package for hospitals covers diagnostics for a much wider range of medical conditions than the equivalent PHC package (58, 67). Separately, diagnostics for certain specific diseases, including some types of cancer, are available through the Z Benefit Package, which is designed to cover conditions that require prolonged hospitalisation, expensive therapies or other care that can lead to catastrophic health costs (68, 69). Diagnostics for HIV, malaria and TB are available through a Sustainable Development Goals (SDG)-related benefit package.

Lancet Commission tracer conditions: Diagnostics for diabetes, hypertension, HIV and TB are included; those for hepatitis B and syphilis are also included, though it is unclear if they are provided to pregnant women.

Purchasing arrangements: The primary care benefit provider can put in place a Memorandum of Agreement with another health facility to provide diagnostic tests not available in their facility.

Alignment with vertical programs: No information available.

Performance of the scheme: In 2021, diagnostic service providers accounted for 2% of claims. However, diagnostics are also included in other categories such as hospitals with no breakdowns by service provided so the total amount claimed for diagnostics is likely to be higher (55). PhilHealth payments for medicines and laboratory tests for inpatient treatment provided by external pharmacies and diagnostic centres increased more than tenfold between 2013 and 2017 (7).

Access to diagnostics: Diagnostic availability varies widely by geographic region, with even essential diagnostics unavailable in remote regions (70, 71).

Vietnam

Scheme development: The Social Health Insurance (SHI) scheme was introduced in 1992 and has gradually expanded into a nationally compulsory scheme requiring member premiums (72). Coverage includes inpatient and outpatient hospital care in public and government-approved private facilities and other health facilities, as well as transportation services in poor and mountainous areas, up to a cost ceiling (72-74). Financing comes from government budget allocations and premiums.

Policy rationale: The SHI scheme aims to support the government’s move towards UHC (75). No criteria for the inclusion of diagnostics are mentioned in the relevant documentation.

Population coverage: 92% enrolment in 2022 (76) exceeding the target of 80% of the total population set in 2012 (72) but missing the revised target of 100% by 2020 (74).

Financial coverage: The cost ceiling for the treatment of each episode is the equivalent of the total minimum salary over 40 months (72). Costs for each included service are set for all hospitals at the same level by the Ministry of Health (72).

Co-payments or premiums: For employees, pensioners, students and other groups, premiums equal 4.5% of basic monthly salaries. 100% subsidy for 13 groups including people over 90 or under 6 years of age, the poor, army and police force and relatives. 70% subsidy for the near poor, students and farmer households (72, 73). Co-payments are set at 20%, except for groups subsidised 100%, paid directly to the hospital (73, 77). A ceiling on co-payments equivalent to six months’ basic salary exists for those with five years of continuous membership (72). A cap is in place for high-cost technical services (77).

Diagnostics included in the scheme: The benefit package explicitly includes diagnostics (74, 78), with the full list of available diagnostics published (79).
Lancet Commission tracer conditions: All Lancet tracer conditions available: diabetes, hypertension, hepatitis B, syphilis, HIV and TB are included for all, including pregnant women (79).

Purchasing arrangements: Contracting arrangements are in place with both public and private providers, though the public sector predominates. Registered facilities are reimbursed via benefit packages (80). Unregistered facilities can be reimbursed if a reference letter from a registered facilities is provided before patient transfer (81). Each health facility has its own cap of health insurance budget that accounts for previous expenditures and changes in the costs of services and new services based on an approved cost for each service (77).

Alignment with vertical programs: Donor-led HIV programmes are integrated into SHI (62).

Performance of the scheme: Population coverage has gradually increased over the years of the scheme. OOP expenditure remains at about 40% of total health expenditure but there is some improvement in financial protection (82, 83). There remain challenges to cover the entire population, mitigate against perverse incentives for the reimbursement of high-cost technologies, and protect patients from the increasing financial burden if they access hospitals outside their region (80, 84).

Access to diagnostics: No published data is available on access to diagnostics through SHI.
Appendix 3
(Figure 1 and 2 separately attached as pdf)

Figure 1. Universal health coverage index, 2017 and 2019
Figure 2. Current annual health expenditure per capita, 2019

- Pakistan: 39 USD
- Nepal: 53 USD
- India: 64 USD
- Cambodia: 113 USD
- Indonesia: 120 USD
- Philippines: 142 USD
- Vietnam: 181 USD
- LMICs: 94 USD
Table 1. Health financing indicators, 2019

<table>
<thead>
<tr>
<th></th>
<th>Cambodia</th>
<th>India</th>
<th>Indonesia</th>
<th>Nepal</th>
<th>Pakistan</th>
<th>Philippines</th>
<th>Viet Nam</th>
<th>LMIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government health expenditure as % GDP</td>
<td>1.7</td>
<td>1.0</td>
<td>1.4</td>
<td>1.1</td>
<td>1.1</td>
<td>1.7</td>
<td>2.38</td>
<td>1.4</td>
</tr>
<tr>
<td>General government health expenditure as % general government expenditure</td>
<td>7.0</td>
<td>3.4</td>
<td>8.7</td>
<td>4.0</td>
<td>4.9</td>
<td>7.6</td>
<td>10.1</td>
<td>5.7</td>
</tr>
<tr>
<td>General government health expenditure per capita (current US$)</td>
<td>27.5</td>
<td>20.9</td>
<td>58.8</td>
<td>13.2</td>
<td>12.6</td>
<td>57.7</td>
<td>79.2</td>
<td>36.8</td>
</tr>
<tr>
<td>General government health expenditure as % current health expenditure</td>
<td>24.3</td>
<td>32.8</td>
<td>48.9</td>
<td>24.8</td>
<td>32.0</td>
<td>40.6</td>
<td>43.8</td>
<td>39.1</td>
</tr>
<tr>
<td>Out-of-pocket spending as % current health expenditure</td>
<td>64.4</td>
<td>54.8</td>
<td>34.8</td>
<td>57.9</td>
<td>53.8</td>
<td>48.6</td>
<td>43.0</td>
<td>48.1</td>
</tr>
<tr>
<td>External as a % current health expenditure</td>
<td>6.5</td>
<td>0.8</td>
<td>0.6</td>
<td>11.9</td>
<td>7.1</td>
<td>0.4</td>
<td>1.0</td>
<td>2.9</td>
</tr>
</tbody>
</table>

Source: Global Health Expenditure Database, 2022. Note: Data point for general government health expenditure as a % general government expenditure for LMIC is from 2018.